HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on BridgeBio Pharma (NASDAQ:BBIO) and maintained a price target of $43.
August 05, 2024 | 10:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on BridgeBio Pharma and maintained a price target of $43.
The reiteration of a Buy rating and maintenance of a $43 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100